Table 2. Demographics and baseline characteristics of patients enrolled in the phase 2b portion by treatment group.
| PAN+AZA (n=40) | AZA (n=42) | All patients (N=82) | |
|---|---|---|---|
| Age, median (range), years | 68 (44–81) | 72 (42–85) | 71 (42–85) |
| Female/male, % | 27.5/72.5 | 40.5/59.5 | 34.1/65.9 |
| Disease, n (%) | |||
| MDS | 25 (62.5) | 22 (52.4) | 47 (57.3) |
| CMML | 6 (15.0) | 7 (16.7) | 13 (15.9) |
| AML | 9 (22.5) | 13 (31.0) | 22 (26.8) |
| ECOG PS, n (%) | |||
| 0 | 14 (35.0) | 20 (47.6) | 34 (41.5) |
| 1 | 25 (62.5) | 18 (42.9) | 43 (52.4) |
| 2 | 1 (2.5) | 4 (9.5) | 5 (6.1) |
Abbreviations: AML, acute myeloid leukemia; AZA, azacitidine; CMML, chronic myelomonocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; MDS, myelodysplastic syndromes; PAN, panobinostat.